Latest news and press releases about Bio-Techne Corporation (TECH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Price
| Price | $72.58 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 62.41 |
| Price / Book | 5.23 |
| EV / EBITDA | 32.15 |
| Dividend Yield | 0.45% |
Profitability
| Return on Equity | 8.63% |
| Return on Invested Capital | 7.52% |
| Return on Assets | 6.79% |
| Gross Margin | 65.77% |
| Operating Margin | 20.73% |
| Net Margin | 14.97% |
Related companies: BMRN · CAI · CORT · EXEL · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of TECH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks